Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controll...

Por Rajkumar, SV, Greipp, P R, Jacobus, S, Callander, N S, Fonseca, R, Vesole, DH, Williams, ME, Abonour, R, Siegel, DS, Katz, M
Publicado em 2009

Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 random...

Por Biran, N, Jacobus, S, Vesole, D H, Callander, N S, Fonseca, R, Williams, M E, Abonour, R, Katz, M S, Rajkumar, S V, Greipp, P R, Siegel, D S
Publicado no Blood Cancer J (2016)

Impact of high-risk classification by FISH: An Eastern Cooperative Oncology Group (ECOG) study E4A03

Por Jacobus, S. J., Kumar, S., Uno, H., Van Wier, S. A., Ahmann, G. J., Henderson, K. J., Callander, N. S., Williams, M. E., Siegel, D. S., Greipp, P. R., Rajkumar, S. V., Fonseca, R.
Publicado em 2011

RELATIONSHIP BETWEEN ELEVATED IMMUNOGLOBULIN FREE LIGHT CHAIN AND THE PRESENCE OF IgH TRANSLOCATIONS IN MULTIPLE MYELOMA

Por Kumar, S., Zhang, L., Dispenzieri, A., Van Wier, S., Katzmann, J.A., Snyder, M., Blood, E., DeGoey, R., Henderson, K., Kyle, R.A., Bradwell, A.R., Greipp, P.R., Rajkumar, S.V., Fonseca, R
Publicado em 2010